X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA FRESENIUS KABI ONCO. GLENMARK PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 13.6 22.1 61.6% View Chart
P/BV x 3.8 3.1 122.7% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 GLENMARK PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-16
FRESENIUS KABI ONCO.
Mar-13
GLENMARK PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,262176 717.0%   
Low Rs67279 855.4%   
Sales per share (Unadj.) Rs270.637.7 717.9%  
Earnings per share (Unadj.) Rs24.95.1 488.4%  
Cash flow per share (Unadj.) Rs34.46.7 511.9%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs151.342.5 355.7%  
Shares outstanding (eoy) m282.16158.23 178.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.63.4 105.8%   
Avg P/E ratio x38.925.0 155.5%  
P/CF ratio (eoy) x28.118.9 148.4%  
Price / Book Value ratio x6.43.0 213.6%  
Dividend payout %8.00-   
Avg Mkt Cap Rs m272,77820,135 1,354.8%   
No. of employees `00010.01.2 870.2%   
Total wages/salary Rs m13,782703 1,959.9%   
Avg. sales/employee Rs Th7,614.95,176.2 147.1%   
Avg. wages/employee Rs Th1,374.8610.4 225.2%   
Avg. net profit/employee Rs Th700.2699.6 100.1%   
INCOME DATA
Net Sales Rs m76,3405,963 1,280.2%  
Other income Rs m35618 1,979.0%   
Total revenues Rs m76,6965,981 1,282.3%   
Gross profit Rs m14,1721,430 991.0%  
Depreciation Rs m2,691258 1,043.6%   
Interest Rs m1,789-26 -6,880.4%   
Profit before tax Rs m10,0481,216 826.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m3,028342 885.0%   
Profit after tax Rs m7,019806 871.0%  
Gross profit margin %18.624.0 77.4%  
Effective tax rate %30.128.1 107.1%   
Net profit margin %9.213.5 68.0%  
BALANCE SHEET DATA
Current assets Rs m59,0965,102 1,158.4%   
Current liabilities Rs m40,0182,385 1,677.6%   
Net working cap to sales %25.045.6 54.9%  
Current ratio x1.52.1 69.1%  
Inventory Days Days75150 50.0%  
Debtors Days Days119113 105.2%  
Net fixed assets Rs m39,0755,148 759.0%   
Share capital Rs m282158 178.4%   
"Free" reserves Rs m30,2816,556 461.9%   
Net worth Rs m42,7036,732 634.3%   
Long term debt Rs m24,873952 2,612.2%   
Total assets Rs m111,02610,388 1,068.8%  
Interest coverage x6.6-45.8 -14.5%   
Debt to equity ratio x0.60.1 411.8%  
Sales to assets ratio x0.70.6 119.8%   
Return on assets %7.97.5 105.7%  
Return on equity %16.412.0 137.3%  
Return on capital %17.514.6 119.9%  
Exports to sales %43.374.5 58.1%   
Imports to sales %7.424.8 30.0%   
Exports (fob) Rs m33,0444,441 744.1%   
Imports (cif) Rs m5,6721,477 383.9%   
Fx inflow Rs m36,9455,298 697.4%   
Fx outflow Rs m61,0661,772 3,445.8%   
Net fx Rs m-24,1223,525 -684.2%   
CASH FLOW
From Operations Rs m3,4491,274 270.7%  
From Investments Rs m-8,802-1,204 730.9%  
From Financial Activity Rs m6,986-196 -3,562.5%  
Net Cashflow Rs m934-126 -739.4%  

Share Holding

Indian Promoters % 48.3 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 6.9 0.3 2,300.0%  
FIIs % 34.4 9.6 358.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 9.1 115.4%  
Shareholders   56,727 42,599 133.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   PANACEA BIOTECH  BIOCON LTD  UNICHEM LAB  NATCO PHARMA  AJANTA PHARMA  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Aug 23, 2017 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS